Vita Life Sciences Limited · ASX:VLS

Vita Life Sciences — Shareholder Meeting (March 2016)

23 slides from Vita Life Sciences's shareholder meeting presentation, Mar 31, 2016

  1. Slide 1: Welcome to the 2012 Vita Life Sciences Limited Annual General Meeting

    Welcome to the 2012 Vita Life Sciences Limited Annual General Meeting 16 May 2012 ASX Code: VSC

  2. Slide 2: Chairman's Welcome Address

    Chairman’s Welcome Address

  3. Slide 3: Chairman's Welcome Address

    1 Chairman 1. Chairman’s s Welcome Address 2. Managing Director’s Review 3. Ordinary & Special Resolutions 4. Question & Answer Time

  4. Slide 4: Managing Directors Review

    Managing Directors Review

  5. Slide 5: MLM Company awarded

    MLM Company awarded: “The 7th Asia “Th A i PPacific ifi SSuper E Excellence ll B Brand d 2011 for Leadership Excellence in Brand Development and Management Organization ” awarded: “The The 2011 Asia Pacific BrandLaureate for Best Brands in Wellness – Supplements”

  6. Slide 6: Solid sales growth of 15.6%

     Solid sales growth of 15.6%  Record PBT of $1.40 million  Strong balance sheet and no debt – Shareholders’ funds of $8.96 million  Maintained dividend trend of 0.5 cents per share  The Th Group’s G ’ brands b d continue ti to t build b ild th their i presence in 8 countries

  7. Slide 7: Australia, Malaysia, Singapore

    Australia  14.1% sales growth y-o-y basis  Herbs of Gold Products sold in more than 750 health foods stores  Vita Science sold into around 150 pharmacies, with sales growth of 46.9% over 2010 Malaysia  20.4% sales growth yy-o-y o y basis in established business local currency  Selling to more t

  8. Slide 8: Sales growth

    2010 2011 Singapore Singapore 16% 19% Australia Australia 45% 45% Others Others 2% 2% Malaysia M l i Malaysia 37% 34%  Sales S l growth h on y-o-y basis b ffor Australia, l Malaysia l and d Singapore were 14.1%, 20.4% and 3.0% respectively (in local currencies)  Australia remains largest contribut

  9. Slide 9: Thailand, MLM Malaysia, China, Vietnam and Indonesia

    Thailand  58.5% sales growth and profitable  Products P d t reach h in i more than th 2,000 2 000 pharmaceutical h ti l outlets Multi-Level Multi Level Marketing in Malaysia  Contributed 9.2% of Group sales with sales growth of 66.8%  Lower loss in 2011 China  Sales grew by 215% and made a smal

  10. Slide 10: 2011 Sales grew by 15.6%

    Revenue ‐ $'m 24 30 24.30  2011 Sales ggrew by y 15.6% despite the stronger A$ 21.00 17.70  New Business units sales are small but gaining traction, contributed 11.0% in 2011 (2010: 7.2%, 2009:2.4%)  MLM business unit now contributes 9.2% 9 2% (6.7% (6 7% in 2010) 2009 2010 2011

  11. Slide 11: Products sold in 8 major countries

    Present: Products sold in 8 major countries Total population of 8 countries:1,812 million World’s World s population (April 2012) : 6,974 million Coverage : 26% In 2005: Products sold in 3 major countries Coverage (at current population): 0.8%

  12. Slide 12: GDP per capita (US$)

    World Economic Outlook, April 2012 Country/ Population 2010 2011 2012 2013 2014 2015 2016 2017 (million) GDP pper 8 418 8,418 9 700 9,700 10 467 10,467 11 099 11,099 11 803 11,803 12 551 12,551 13 347 13,347 14 194 14,194 Malaysia capital (US$) (28.8) Inflation (%) 1.7 3.2 2.7 2.5 2.5 2.5 2.5 2.5 GD

  13. Slide 13: Year ended 31 December

    Year ended 31 December 2010 2011 A$'million $ A$'million $ Revenue 20.99 24.27 Profit Before Tax 4.92 1.57 Profit After Tax 4.46 1.21 Shareholders' Funds 8.13 8.96 Cash 0.46 3.63 Borrowings (1.81) -

  14. Slide 14: Income Statement ($ million)

    Income Statement ($ million) 2010 2011 % Change EBIT 4.90 1.57 <100% (Less)/Add: Extraordinary items Net External PAN (income)/costs (4.10) - 100% Underlying EBIT 0 80 0.80 1 57 1.57 95% Interest expense (0.29) (0.16) -43% Underlying y g net p profit bef tax 0.51 1.40 174% Income tax expense (0.17)

  15. Slide 15: Strong balance sheet with no debt

    Balance Sheet ($ m) 2010 2011 Current assets 12.23 10.93  Strong balance sheet with Non-current assets 2.29 2.42 no debt Total assets 14.51 13.35  Net assets increased to Current liabilities (6.38) (4.37) $8.9m, tripled since 2007 Non-current liabilities (0.01) (0.03)  40% of Net Assets made up T

  16. Slide 16: Established Business Units to perform consistently

     Established Business Units to perform consistently with stable growth  New Business units expected to continue extending Group’s expansion strategy gy in China,, Malaysia y and Thailand  Continued focus on sales, market share, profitability and expenditure control  Management reports indicate s

  17. Slide 17: Unaudited management reports showed record first quarter sales

     Unaudited management reports showed record first quarter sales  Exceeded the expected 15% sales growth as forecast in the 2011 Financial Statements  Expect this trend to continue throughout the year  Sales to June 2012 forecast to exceed the corresponding period in 2011 by between 20% and 25% (

  18. Slide 18: Dividend Payout Ratio

    Dividend Payout Ratio  Dividends of 0.5 cents per share 24% paid for financial year 2011 and 2010  Dividend payout ratio of 24% PAT with 76% reinvested in the operations  Strength of earnings and positive 6% operational cash may allow interim and annual dividend for 2012 0% 2009 2010 2011

  19. Slide 19: Chairman's Address

    1. Chairman Chairman’s s Address 2. Managing Director’s Review 3. Ordinary & Special Resolutions 4 Question 4. Q ti & Answer A Ti Time

  20. Slide 20: Remuneration Report

    1. Remuneration Report 2. Election of Director – John Sharman 3. Election of Director – Henry Townsing 4. Share buy-back 5 Long 5. L Term T Incentive I ti Plan Pl – Grant G t off a limited recourse loan to Managing Director

  21. Slide 21: Resolutions voting results

    PROXY’S RESOLUTIONS IN FAVOUR AGAINST ABSTAIN TOTALS DISCRETION 1) Adoption of the Remuneration 37,082,696 33,442 2,410,095 5,021 39,531,254 Report 2) Election of Director (Mr J 39,243.038 - 283,195 5,021 39,531,254 Sharman) 3) Election of Director (Mr H 39 056 025 39,056,025 - 470 208 470,208 5 021

  22. Slide 22: Chairman's Address

    1. Chairman Chairman’s s Address 2. Managing Director’s Review 3. Ordinary & Special Resolutions 4 Question 4. Q ti & Answer A Ti Time

  23. Slide 23: Thank You

    Th k You Thank Y 16 May 2012

Vita Life Sciences — Shareholder Meeting (March 2016) on 6ix